Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Cancer Institute (NCI)
OBJECTIVES:
I. Evaluate the clinical effectiveness of flavopiridol in patients with metastatic androgen independent adenocarcinoma of the prostate.
II. Assess the toxic effects of flavopiridol in this patient population.
OUTLINE:
Patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4 courses. After 2 courses of treatment, patients not experiencing unacceptable toxic effects may receive a dose escalation. Patients are followed every 3 months until death.
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
PATIENT CHARACTERISTICS:
Performance Status: ECOG 0-2
Life Expectancy: At least 3 months
WBC at least 3,000/mm3
Absolute neutrophil count at least 1,200/mm3
Platelet count at least 100,000/mm3
Hemoglobin at least 8 g/dL
Bilirubin no greater than 1.5 mg/dL
SGOT no greater than 2.5 times normal
Creatinine no greater than 1.5 mg/dL
Prostate-specific antigen at least 10 ng/mL (if bone only disease)
No prior or concurrent maligancies within 5 years, except nonmelanoma skin cancer
No serious medical illness
No cord compression symptoms
PRIOR CONCURRENT THERAPY:
No prior chemotherapy
No prior suramin therapy
Prior or concurrent use of luteinizing hormone-releasing hormone allowed (no other concurrent hormonal therapy)
No prior anti-androgen therapy within 4 weeks of study
